Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.59 |
| ▸ | MAOA | P21397 | 6/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.51 |
| ▸ | RXRG | P48443 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408 | 0.88 | NR4A2 (0.59) | MAOBMAOANR4A2ENPP2PKM | |
| SCHEMBL15330536 | 0.82 | NR4A2 (0.56) | MAOBMAOANR4A2ENPP2PKM | |
| SCHEMBL31051000 | 0.82 | NR4A2 (0.56) | MAOBMAOANR4A2ENPP2PKM | |
| Methyl Alcohol SCHEMBL9626623 | 0.79 | RXRA (0.68) | MAOBMAOANR4A2ENPP2PKM | |
| SCHEMBL4698486 | 0.79 | NR4A2 (0.66) | MAOBMAOANR4A2PKMRXRA | |
| SCHEMBL31580931 | 0.78 | ENPP2 (0.56) | MAOBMAOANR4A2ENPP2PKM | |
| SCHEMBL2563261 | 0.78 | MAOB (0.65) | MAOBMAOANR4A2ENPP2PKM | |
| SCHEMBL31580896 | 0.78 | MAOB (0.65) | MAOBMAOANR4A2ENPP2PKM | |
| SCHEMBL12030885 | 0.77 | NR4A2 (0.64) | MAOBMAOANR4A2PKMRXRA | |
| SCHEMBL791896 | 0.77 | MAOB (0.70) | MAOBMAOANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2399585-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MAOB 780/4885MAOA 809/4885NR4A2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.